nodes	percent_of_prediction	percent_of_DWPC	metapath
Risedronate—PTGS2—urinary bladder cancer	0.592	1	CbGaD
Risedronate—PTGS2—Cisplatin—urinary bladder cancer	0.0841	0.504	CbGbCtD
Risedronate—PTGS2—Etoposide—urinary bladder cancer	0.0826	0.496	CbGbCtD
Risedronate—FDPS—SREBP signalling—AMFR—urinary bladder cancer	0.0058	0.184	CbGpPWpGaD
Risedronate—FDPS—prostate gland—urinary bladder cancer	0.00458	0.132	CbGeAlD
Risedronate—FDPS—seminal vesicle—urinary bladder cancer	0.00387	0.112	CbGeAlD
Risedronate—FDPS—smooth muscle tissue—urinary bladder cancer	0.00324	0.0936	CbGeAlD
Risedronate—FDPS—renal system—urinary bladder cancer	0.00312	0.0901	CbGeAlD
Risedronate—FDPS—urethra—urinary bladder cancer	0.00307	0.0885	CbGeAlD
Risedronate—FDPS—female reproductive system—urinary bladder cancer	0.0025	0.0722	CbGeAlD
Risedronate—FDPS—vagina—urinary bladder cancer	0.00226	0.0653	CbGeAlD
Risedronate—PTGS2—prostate gland—urinary bladder cancer	0.00175	0.0507	CbGeAlD
Risedronate—PTGS2—seminal vesicle—urinary bladder cancer	0.00148	0.0429	CbGeAlD
Risedronate—FDPS—lymph node—urinary bladder cancer	0.00146	0.0422	CbGeAlD
Risedronate—PTGS2—Synthesis of 15-eicosatetraenoic acid derivatives—GPX1—urinary bladder cancer	0.00146	0.0463	CbGpPWpGaD
Risedronate—PTGS2—epithelium—urinary bladder cancer	0.00129	0.0372	CbGeAlD
Risedronate—PTGS2—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—HPGDS—urinary bladder cancer	0.00125	0.0397	CbGpPWpGaD
Risedronate—PTGS2—smooth muscle tissue—urinary bladder cancer	0.00124	0.0359	CbGeAlD
Risedronate—PTGS2—renal system—urinary bladder cancer	0.0012	0.0345	CbGeAlD
Risedronate—PTGS2—urethra—urinary bladder cancer	0.00118	0.0339	CbGeAlD
Risedronate—FDPS—Activation of gene expression by SREBF (SREBP)—CREBBP—urinary bladder cancer	0.000961	0.0305	CbGpPWpGaD
Risedronate—PTGS2—female reproductive system—urinary bladder cancer	0.000958	0.0277	CbGeAlD
Risedronate—PTGS2—vagina—urinary bladder cancer	0.000866	0.025	CbGeAlD
Risedronate—PTGS2—Arachidonic acid metabolism—CYP4B1—urinary bladder cancer	0.000851	0.027	CbGpPWpGaD
Risedronate—FDPS—Regulation of cholesterol biosynthesis by SREBP (SREBF)—CREBBP—urinary bladder cancer	0.000767	0.0243	CbGpPWpGaD
Risedronate—PTGS2—C-MYB transcription factor network—PTCRA—urinary bladder cancer	0.000682	0.0216	CbGpPWpGaD
Risedronate—PTGS2—Defective AMN causes hereditary megaloblastic anemia 1—GSTO2—urinary bladder cancer	0.000663	0.021	CbGpPWpGaD
Risedronate—FDPS—SREBP signalling—PPARG—urinary bladder cancer	0.000647	0.0205	CbGpPWpGaD
Risedronate—PTGS2—lymph node—urinary bladder cancer	0.00056	0.0162	CbGeAlD
Risedronate—PTGS2—Defective AMN causes hereditary megaloblastic anemia 1—SLC19A1—urinary bladder cancer	0.000516	0.0164	CbGpPWpGaD
Risedronate—FDPS—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	0.000508	0.0161	CbGpPWpGaD
Risedronate—PTGS2—Defective AMN causes hereditary megaloblastic anemia 1—PRSS3—urinary bladder cancer	0.000503	0.0159	CbGpPWpGaD
Risedronate—PTGS2—Aryl Hydrocarbon Receptor—HPGDS—urinary bladder cancer	0.000484	0.0153	CbGpPWpGaD
Risedronate—PTGS2—Arachidonic acid metabolism—HPGDS—urinary bladder cancer	0.000453	0.0143	CbGpPWpGaD
Risedronate—PTGS2—Aryl Hydrocarbon Receptor—NQO1—urinary bladder cancer	0.00039	0.0124	CbGpPWpGaD
Risedronate—PTGS2—S1P1 pathway—RHOA—urinary bladder cancer	0.000378	0.012	CbGpPWpGaD
Risedronate—PTGS2—C-MYB transcription factor network—BIRC3—urinary bladder cancer	0.000345	0.0109	CbGpPWpGaD
Risedronate—PTGS2—Overview of nanoparticle effects—CXCL8—urinary bladder cancer	0.000332	0.0105	CbGpPWpGaD
Risedronate—PTGS2—C-MYB transcription factor network—MPO—urinary bladder cancer	0.000295	0.00936	CbGpPWpGaD
Risedronate—PTGS2—Signaling mediated by p38-alpha and p38-beta—ESR1—urinary bladder cancer	0.000292	0.00926	CbGpPWpGaD
Risedronate—FDPS—Metabolism—GSTZ1—urinary bladder cancer	0.00029	0.00918	CbGpPWpGaD
Risedronate—PTGS2—Selenium Micronutrient Network—MPO—urinary bladder cancer	0.000284	0.00901	CbGpPWpGaD
Risedronate—FDPS—Metabolism—GSTO2—urinary bladder cancer	0.000275	0.0087	CbGpPWpGaD
Risedronate—FDPS—Metabolism—NAT1—urinary bladder cancer	0.000275	0.0087	CbGpPWpGaD
Risedronate—FDPS—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	0.00027	0.00856	CbGpPWpGaD
Risedronate—PTGS2—Arachidonic acid metabolism—GPX1—urinary bladder cancer	0.000268	0.00849	CbGpPWpGaD
Risedronate—FDPS—Metabolism—UGT2B7—urinary bladder cancer	0.000251	0.00796	CbGpPWpGaD
Risedronate—PTGS2—Aryl Hydrocarbon Receptor—ESR1—urinary bladder cancer	0.000235	0.00744	CbGpPWpGaD
Risedronate—PTGS2—Overview of nanoparticle effects—TNF—urinary bladder cancer	0.000231	0.00732	CbGpPWpGaD
Risedronate—FDPS—Metabolism—CYP4B1—urinary bladder cancer	0.000226	0.00717	CbGpPWpGaD
Risedronate—PTGS2—Calcium signaling in the CD4+ TCR pathway—IL2—urinary bladder cancer	0.000226	0.00716	CbGpPWpGaD
Risedronate—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CDK4—urinary bladder cancer	0.000221	0.00699	CbGpPWpGaD
Risedronate—FDPS—Metabolism—SLC19A1—urinary bladder cancer	0.000214	0.00677	CbGpPWpGaD
Risedronate—FDPS—Metabolism—PRSS3—urinary bladder cancer	0.000208	0.0066	CbGpPWpGaD
Risedronate—PTGS2—Aryl Hydrocarbon Receptor—RB1—urinary bladder cancer	0.000205	0.0065	CbGpPWpGaD
Risedronate—PTGS2—Integrated Pancreatic Cancer Pathway—LIG1—urinary bladder cancer	0.000203	0.00644	CbGpPWpGaD
Risedronate—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—PPARG—urinary bladder cancer	0.0002	0.00635	CbGpPWpGaD
Risedronate—Pneumonia—Methotrexate—urinary bladder cancer	0.000194	0.00111	CcSEcCtD
Risedronate—Nasopharyngitis—Doxorubicin—urinary bladder cancer	0.000194	0.00111	CcSEcCtD
Risedronate—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	0.000194	0.00111	CcSEcCtD
Risedronate—Infestation—Methotrexate—urinary bladder cancer	0.000193	0.0011	CcSEcCtD
Risedronate—Infestation NOS—Methotrexate—urinary bladder cancer	0.000193	0.0011	CcSEcCtD
Risedronate—Depression—Methotrexate—urinary bladder cancer	0.000193	0.0011	CcSEcCtD
Risedronate—Gastritis—Doxorubicin—urinary bladder cancer	0.000192	0.0011	CcSEcCtD
Risedronate—Pain—Cisplatin—urinary bladder cancer	0.000192	0.0011	CcSEcCtD
Risedronate—Muscular weakness—Doxorubicin—urinary bladder cancer	0.000191	0.00109	CcSEcCtD
Risedronate—Body temperature increased—Gemcitabine—urinary bladder cancer	0.00019	0.00109	CcSEcCtD
Risedronate—Dizziness—Thiotepa—urinary bladder cancer	0.000189	0.00108	CcSEcCtD
Risedronate—Abdominal distension—Doxorubicin—urinary bladder cancer	0.000189	0.00108	CcSEcCtD
Risedronate—Upper respiratory tract infection—Epirubicin—urinary bladder cancer	0.000188	0.00108	CcSEcCtD
Risedronate—Urticaria—Fluorouracil—urinary bladder cancer	0.000188	0.00108	CcSEcCtD
Risedronate—Conjunctivitis—Methotrexate—urinary bladder cancer	0.000188	0.00107	CcSEcCtD
Risedronate—Asthma—Doxorubicin—urinary bladder cancer	0.000188	0.00107	CcSEcCtD
Risedronate—Influenza—Doxorubicin—urinary bladder cancer	0.000188	0.00107	CcSEcCtD
Risedronate—Body temperature increased—Fluorouracil—urinary bladder cancer	0.000187	0.00107	CcSEcCtD
Risedronate—Paraesthesia—Etoposide—urinary bladder cancer	0.000185	0.00106	CcSEcCtD
Risedronate—PTGS2—C-MYB transcription factor network—GSTM1—urinary bladder cancer	0.000185	0.00585	CbGpPWpGaD
Risedronate—PTGS2—C-MYB transcription factor network—NCOR1—urinary bladder cancer	0.000185	0.00585	CbGpPWpGaD
Risedronate—Dyspnoea—Etoposide—urinary bladder cancer	0.000183	0.00105	CcSEcCtD
Risedronate—Angina pectoris—Doxorubicin—urinary bladder cancer	0.000183	0.00104	CcSEcCtD
Risedronate—Hepatobiliary disease—Methotrexate—urinary bladder cancer	0.000183	0.00104	CcSEcCtD
Risedronate—Vomiting—Thiotepa—urinary bladder cancer	0.000182	0.00104	CcSEcCtD
Risedronate—Pneumonia—Epirubicin—urinary bladder cancer	0.000182	0.00104	CcSEcCtD
Risedronate—Infestation NOS—Epirubicin—urinary bladder cancer	0.000181	0.00103	CcSEcCtD
Risedronate—Infestation—Epirubicin—urinary bladder cancer	0.000181	0.00103	CcSEcCtD
Risedronate—Rash—Thiotepa—urinary bladder cancer	0.000181	0.00103	CcSEcCtD
Risedronate—Bronchitis—Doxorubicin—urinary bladder cancer	0.00018	0.00103	CcSEcCtD
Risedronate—Dermatitis—Thiotepa—urinary bladder cancer	0.00018	0.00103	CcSEcCtD
Risedronate—Headache—Thiotepa—urinary bladder cancer	0.000179	0.00103	CcSEcCtD
Risedronate—PTGS2—Selenium Micronutrient Network—SOD2—urinary bladder cancer	0.000179	0.00566	CbGpPWpGaD
Risedronate—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.000178	0.00101	CcSEcCtD
Risedronate—Body temperature increased—Cisplatin—urinary bladder cancer	0.000177	0.00101	CcSEcCtD
Risedronate—Fatigue—Etoposide—urinary bladder cancer	0.000177	0.00101	CcSEcCtD
Risedronate—Pain—Etoposide—urinary bladder cancer	0.000176	0.00101	CcSEcCtD
Risedronate—Constipation—Etoposide—urinary bladder cancer	0.000176	0.00101	CcSEcCtD
Risedronate—Conjunctivitis—Epirubicin—urinary bladder cancer	0.000176	0.001	CcSEcCtD
Risedronate—Urinary tract infection—Epirubicin—urinary bladder cancer	0.000176	0.001	CcSEcCtD
Risedronate—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.000175	0.000997	CcSEcCtD
Risedronate—Upper respiratory tract infection—Doxorubicin—urinary bladder cancer	0.000174	0.000996	CcSEcCtD
Risedronate—Haemoglobin—Methotrexate—urinary bladder cancer	0.000174	0.000996	CcSEcCtD
Risedronate—Haemorrhage—Methotrexate—urinary bladder cancer	0.000173	0.000991	CcSEcCtD
Risedronate—Asthenia—Gemcitabine—urinary bladder cancer	0.000173	0.000988	CcSEcCtD
Risedronate—Pharyngitis—Methotrexate—urinary bladder cancer	0.000172	0.000984	CcSEcCtD
Risedronate—Urinary tract disorder—Methotrexate—urinary bladder cancer	0.000171	0.000979	CcSEcCtD
Risedronate—Hepatobiliary disease—Epirubicin—urinary bladder cancer	0.000171	0.000977	CcSEcCtD
Risedronate—Pruritus—Gemcitabine—urinary bladder cancer	0.00017	0.000974	CcSEcCtD
Risedronate—PTGS2—Selenium Micronutrient Network—GPX1—urinary bladder cancer	0.00017	0.0054	CbGpPWpGaD
Risedronate—Nausea—Thiotepa—urinary bladder cancer	0.00017	0.000972	CcSEcCtD
Risedronate—Urethral disorder—Methotrexate—urinary bladder cancer	0.00017	0.000971	CcSEcCtD
Risedronate—Sinusitis—Epirubicin—urinary bladder cancer	0.00017	0.000969	CcSEcCtD
Risedronate—Pneumonia—Doxorubicin—urinary bladder cancer	0.000168	0.000961	CcSEcCtD
Risedronate—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.000168	0.000961	CcSEcCtD
Risedronate—Pruritus—Fluorouracil—urinary bladder cancer	0.000168	0.000958	CcSEcCtD
Risedronate—Infestation NOS—Doxorubicin—urinary bladder cancer	0.000167	0.000956	CcSEcCtD
Risedronate—Infestation—Doxorubicin—urinary bladder cancer	0.000167	0.000956	CcSEcCtD
Risedronate—FDPS—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	0.000167	0.00529	CbGpPWpGaD
Risedronate—FDPS—Metabolism—TYMP—urinary bladder cancer	0.000166	0.00527	CbGpPWpGaD
Risedronate—Hypersensitivity—Cisplatin—urinary bladder cancer	0.000165	0.000945	CcSEcCtD
Risedronate—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000165	0.000942	CcSEcCtD
Risedronate—Urticaria—Etoposide—urinary bladder cancer	0.000163	0.000934	CcSEcCtD
Risedronate—Haemoglobin—Epirubicin—urinary bladder cancer	0.000163	0.000932	CcSEcCtD
Risedronate—Rhinitis—Epirubicin—urinary bladder cancer	0.000163	0.00093	CcSEcCtD
Risedronate—Abdominal pain—Etoposide—urinary bladder cancer	0.000163	0.000929	CcSEcCtD
Risedronate—Body temperature increased—Etoposide—urinary bladder cancer	0.000163	0.000929	CcSEcCtD
Risedronate—Conjunctivitis—Doxorubicin—urinary bladder cancer	0.000163	0.000929	CcSEcCtD
Risedronate—Urinary tract infection—Doxorubicin—urinary bladder cancer	0.000163	0.000929	CcSEcCtD
Risedronate—Haemorrhage—Epirubicin—urinary bladder cancer	0.000162	0.000927	CcSEcCtD
Risedronate—Eye disorder—Methotrexate—urinary bladder cancer	0.000162	0.000926	CcSEcCtD
Risedronate—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000162	0.000926	CcSEcCtD
Risedronate—Tinnitus—Methotrexate—urinary bladder cancer	0.000162	0.000924	CcSEcCtD
Risedronate—Asthenia—Cisplatin—urinary bladder cancer	0.000161	0.000921	CcSEcCtD
Risedronate—Pharyngitis—Epirubicin—urinary bladder cancer	0.000161	0.00092	CcSEcCtD
Risedronate—Cardiac disorder—Methotrexate—urinary bladder cancer	0.000161	0.00092	CcSEcCtD
Risedronate—Urinary tract disorder—Epirubicin—urinary bladder cancer	0.00016	0.000916	CcSEcCtD
Risedronate—Oedema peripheral—Epirubicin—urinary bladder cancer	0.00016	0.000914	CcSEcCtD
Risedronate—FDPS—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	0.00016	0.00506	CbGpPWpGaD
Risedronate—Connective tissue disorder—Epirubicin—urinary bladder cancer	0.000159	0.000911	CcSEcCtD
Risedronate—Urethral disorder—Epirubicin—urinary bladder cancer	0.000159	0.000909	CcSEcCtD
Risedronate—PTGS2—Defective AMN causes hereditary megaloblastic anemia 1—MTHFR—urinary bladder cancer	0.000159	0.00503	CbGpPWpGaD
Risedronate—Hepatobiliary disease—Doxorubicin—urinary bladder cancer	0.000158	0.000904	CcSEcCtD
Risedronate—Angiopathy—Methotrexate—urinary bladder cancer	0.000157	0.000899	CcSEcCtD
Risedronate—PTGS2—Selenium Micronutrient Network—MTHFR—urinary bladder cancer	0.000157	0.00498	CbGpPWpGaD
Risedronate—Sinusitis—Doxorubicin—urinary bladder cancer	0.000157	0.000897	CcSEcCtD
Risedronate—Immune system disorder—Methotrexate—urinary bladder cancer	0.000157	0.000895	CcSEcCtD
Risedronate—Dizziness—Fluorouracil—urinary bladder cancer	0.000157	0.000895	CcSEcCtD
Risedronate—Mediastinal disorder—Methotrexate—urinary bladder cancer	0.000156	0.000893	CcSEcCtD
Risedronate—PTGS2—Integrated Pancreatic Cancer Pathway—HPGDS—urinary bladder cancer	0.000155	0.00491	CbGpPWpGaD
Risedronate—PTGS2—Integrated Pancreatic Cancer Pathway—IGFBP3—urinary bladder cancer	0.000154	0.00488	CbGpPWpGaD
Risedronate—Diarrhoea—Cisplatin—urinary bladder cancer	0.000154	0.000878	CcSEcCtD
Risedronate—Vomiting—Gemcitabine—urinary bladder cancer	0.000153	0.000875	CcSEcCtD
Risedronate—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CXCL8—urinary bladder cancer	0.000153	0.00485	CbGpPWpGaD
Risedronate—Mental disorder—Methotrexate—urinary bladder cancer	0.000152	0.000868	CcSEcCtD
Risedronate—Rash—Gemcitabine—urinary bladder cancer	0.000152	0.000868	CcSEcCtD
Risedronate—Dermatitis—Gemcitabine—urinary bladder cancer	0.000152	0.000867	CcSEcCtD
Risedronate—Eye disorder—Epirubicin—urinary bladder cancer	0.000152	0.000867	CcSEcCtD
Risedronate—Hypersensitivity—Etoposide—urinary bladder cancer	0.000152	0.000866	CcSEcCtD
Risedronate—Tinnitus—Epirubicin—urinary bladder cancer	0.000151	0.000865	CcSEcCtD
Risedronate—Malnutrition—Methotrexate—urinary bladder cancer	0.000151	0.000863	CcSEcCtD
Risedronate—Haemoglobin—Doxorubicin—urinary bladder cancer	0.000151	0.000862	CcSEcCtD
Risedronate—Headache—Gemcitabine—urinary bladder cancer	0.000151	0.000862	CcSEcCtD
Risedronate—Cardiac disorder—Epirubicin—urinary bladder cancer	0.000151	0.000861	CcSEcCtD
Risedronate—Vomiting—Fluorouracil—urinary bladder cancer	0.000151	0.00086	CcSEcCtD
Risedronate—Rhinitis—Doxorubicin—urinary bladder cancer	0.000151	0.00086	CcSEcCtD
Risedronate—FDPS—Metabolism—NAT2—urinary bladder cancer	0.00015	0.00477	CbGpPWpGaD
Risedronate—Haemorrhage—Doxorubicin—urinary bladder cancer	0.00015	0.000858	CcSEcCtD
Risedronate—Rash—Fluorouracil—urinary bladder cancer	0.000149	0.000853	CcSEcCtD
Risedronate—Dermatitis—Fluorouracil—urinary bladder cancer	0.000149	0.000853	CcSEcCtD
Risedronate—Pharyngitis—Doxorubicin—urinary bladder cancer	0.000149	0.000852	CcSEcCtD
Risedronate—Headache—Fluorouracil—urinary bladder cancer	0.000148	0.000848	CcSEcCtD
Risedronate—Urinary tract disorder—Doxorubicin—urinary bladder cancer	0.000148	0.000847	CcSEcCtD
Risedronate—Oedema peripheral—Doxorubicin—urinary bladder cancer	0.000148	0.000845	CcSEcCtD
Risedronate—Asthenia—Etoposide—urinary bladder cancer	0.000148	0.000843	CcSEcCtD
Risedronate—Connective tissue disorder—Doxorubicin—urinary bladder cancer	0.000148	0.000843	CcSEcCtD
Risedronate—PTGS2—Aryl Hydrocarbon Receptor—CDKN1A—urinary bladder cancer	0.000147	0.00467	CbGpPWpGaD
Risedronate—Angiopathy—Epirubicin—urinary bladder cancer	0.000147	0.000841	CcSEcCtD
Risedronate—Urethral disorder—Doxorubicin—urinary bladder cancer	0.000147	0.000841	CcSEcCtD
Risedronate—Immune system disorder—Epirubicin—urinary bladder cancer	0.000147	0.000838	CcSEcCtD
Risedronate—Mediastinal disorder—Epirubicin—urinary bladder cancer	0.000146	0.000836	CcSEcCtD
Risedronate—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL2—urinary bladder cancer	0.000146	0.00463	CbGpPWpGaD
Risedronate—Back pain—Methotrexate—urinary bladder cancer	0.000146	0.000834	CcSEcCtD
Risedronate—Pruritus—Etoposide—urinary bladder cancer	0.000146	0.000832	CcSEcCtD
Risedronate—Arrhythmia—Epirubicin—urinary bladder cancer	0.000145	0.000828	CcSEcCtD
Risedronate—Nausea—Gemcitabine—urinary bladder cancer	0.000143	0.000818	CcSEcCtD
Risedronate—Vomiting—Cisplatin—urinary bladder cancer	0.000143	0.000816	CcSEcCtD
Risedronate—Mental disorder—Epirubicin—urinary bladder cancer	0.000142	0.000812	CcSEcCtD
Risedronate—Rash—Cisplatin—urinary bladder cancer	0.000142	0.000809	CcSEcCtD
Risedronate—Dermatitis—Cisplatin—urinary bladder cancer	0.000141	0.000808	CcSEcCtD
Risedronate—Malnutrition—Epirubicin—urinary bladder cancer	0.000141	0.000807	CcSEcCtD
Risedronate—Diarrhoea—Etoposide—urinary bladder cancer	0.000141	0.000804	CcSEcCtD
Risedronate—Nausea—Fluorouracil—urinary bladder cancer	0.000141	0.000804	CcSEcCtD
Risedronate—Eye disorder—Doxorubicin—urinary bladder cancer	0.00014	0.000802	CcSEcCtD
Risedronate—PTGS2—Aryl Hydrocarbon Receptor—EP300—urinary bladder cancer	0.00014	0.00444	CbGpPWpGaD
Risedronate—Tinnitus—Doxorubicin—urinary bladder cancer	0.00014	0.0008	CcSEcCtD
Risedronate—Anaemia—Methotrexate—urinary bladder cancer	0.00014	0.000797	CcSEcCtD
Risedronate—Cardiac disorder—Doxorubicin—urinary bladder cancer	0.000139	0.000796	CcSEcCtD
Risedronate—Flatulence—Epirubicin—urinary bladder cancer	0.000139	0.000795	CcSEcCtD
Risedronate—Back pain—Epirubicin—urinary bladder cancer	0.000137	0.000781	CcSEcCtD
Risedronate—PTGS2—Aryl Hydrocarbon Receptor—SRC—urinary bladder cancer	0.000136	0.00432	CbGpPWpGaD
Risedronate—Angiopathy—Doxorubicin—urinary bladder cancer	0.000136	0.000779	CcSEcCtD
Risedronate—Dizziness—Etoposide—urinary bladder cancer	0.000136	0.000777	CcSEcCtD
Risedronate—Muscle spasms—Epirubicin—urinary bladder cancer	0.000136	0.000776	CcSEcCtD
Risedronate—Immune system disorder—Doxorubicin—urinary bladder cancer	0.000136	0.000775	CcSEcCtD
Risedronate—Vertigo—Methotrexate—urinary bladder cancer	0.000136	0.000775	CcSEcCtD
Risedronate—Mediastinal disorder—Doxorubicin—urinary bladder cancer	0.000135	0.000773	CcSEcCtD
Risedronate—Arrhythmia—Doxorubicin—urinary bladder cancer	0.000134	0.000767	CcSEcCtD
Risedronate—Nausea—Cisplatin—urinary bladder cancer	0.000133	0.000762	CcSEcCtD
Risedronate—Cough—Methotrexate—urinary bladder cancer	0.000132	0.000753	CcSEcCtD
Risedronate—Mental disorder—Doxorubicin—urinary bladder cancer	0.000132	0.000752	CcSEcCtD
Risedronate—Vomiting—Etoposide—urinary bladder cancer	0.000131	0.000747	CcSEcCtD
Risedronate—Malnutrition—Doxorubicin—urinary bladder cancer	0.000131	0.000747	CcSEcCtD
Risedronate—Anaemia—Epirubicin—urinary bladder cancer	0.000131	0.000746	CcSEcCtD
Risedronate—FDPS—Metabolism—RRM2—urinary bladder cancer	0.00013	0.00412	CbGpPWpGaD
Risedronate—Rash—Etoposide—urinary bladder cancer	0.00013	0.000741	CcSEcCtD
Risedronate—Dermatitis—Etoposide—urinary bladder cancer	0.00013	0.00074	CcSEcCtD
Risedronate—Headache—Etoposide—urinary bladder cancer	0.000129	0.000736	CcSEcCtD
Risedronate—Flatulence—Doxorubicin—urinary bladder cancer	0.000129	0.000736	CcSEcCtD
Risedronate—Arthralgia—Methotrexate—urinary bladder cancer	0.000129	0.000734	CcSEcCtD
Risedronate—Chest pain—Methotrexate—urinary bladder cancer	0.000129	0.000734	CcSEcCtD
Risedronate—Myalgia—Methotrexate—urinary bladder cancer	0.000129	0.000734	CcSEcCtD
Risedronate—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.000128	0.000729	CcSEcCtD
Risedronate—PTGS2—C-MYB transcription factor network—CREBBP—urinary bladder cancer	0.000127	0.00403	CbGpPWpGaD
Risedronate—Vertigo—Epirubicin—urinary bladder cancer	0.000127	0.000725	CcSEcCtD
Risedronate—Syncope—Epirubicin—urinary bladder cancer	0.000127	0.000724	CcSEcCtD
Risedronate—Back pain—Doxorubicin—urinary bladder cancer	0.000126	0.000723	CcSEcCtD
Risedronate—Muscle spasms—Doxorubicin—urinary bladder cancer	0.000126	0.000718	CcSEcCtD
Risedronate—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—urinary bladder cancer	0.000125	0.00396	CbGpPWpGaD
Risedronate—Loss of consciousness—Epirubicin—urinary bladder cancer	0.000124	0.00071	CcSEcCtD
Risedronate—PTGS2—Integrated Pancreatic Cancer Pathway—ESR2—urinary bladder cancer	0.000124	0.00393	CbGpPWpGaD
Risedronate—Cough—Epirubicin—urinary bladder cancer	0.000123	0.000704	CcSEcCtD
Risedronate—Infection—Methotrexate—urinary bladder cancer	0.000122	0.000699	CcSEcCtD
Risedronate—Nausea—Etoposide—urinary bladder cancer	0.000122	0.000698	CcSEcCtD
Risedronate—PTGS2—Aryl Hydrocarbon Receptor—MYC—urinary bladder cancer	0.000122	0.00387	CbGpPWpGaD
Risedronate—Hypertension—Epirubicin—urinary bladder cancer	0.000122	0.000697	CcSEcCtD
Risedronate—PTGS2—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	0.000122	0.00385	CbGpPWpGaD
Risedronate—Nervous system disorder—Methotrexate—urinary bladder cancer	0.000121	0.00069	CcSEcCtD
Risedronate—Anaemia—Doxorubicin—urinary bladder cancer	0.000121	0.00069	CcSEcCtD
Risedronate—Chest pain—Epirubicin—urinary bladder cancer	0.00012	0.000687	CcSEcCtD
Risedronate—Arthralgia—Epirubicin—urinary bladder cancer	0.00012	0.000687	CcSEcCtD
Risedronate—Myalgia—Epirubicin—urinary bladder cancer	0.00012	0.000687	CcSEcCtD
Risedronate—FDPS—Metabolism—ENO2—urinary bladder cancer	0.00012	0.00381	CbGpPWpGaD
Risedronate—FDPS—Metabolism—HPGDS—urinary bladder cancer	0.00012	0.00381	CbGpPWpGaD
Risedronate—Anxiety—Epirubicin—urinary bladder cancer	0.00012	0.000685	CcSEcCtD
Risedronate—Skin disorder—Methotrexate—urinary bladder cancer	0.00012	0.000684	CcSEcCtD
Risedronate—FDPS—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	0.00012	0.00379	CbGpPWpGaD
Risedronate—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.000119	0.000683	CcSEcCtD
Risedronate—PTGS2—Aryl Hydrocarbon Receptor—EGFR—urinary bladder cancer	0.000119	0.00379	CbGpPWpGaD
Risedronate—Dry mouth—Epirubicin—urinary bladder cancer	0.000118	0.000672	CcSEcCtD
Risedronate—Vertigo—Doxorubicin—urinary bladder cancer	0.000117	0.000671	CcSEcCtD
Risedronate—Syncope—Doxorubicin—urinary bladder cancer	0.000117	0.00067	CcSEcCtD
Risedronate—FDPS—Metabolism—GSTT1—urinary bladder cancer	0.000117	0.0037	CbGpPWpGaD
Risedronate—Loss of consciousness—Doxorubicin—urinary bladder cancer	0.000115	0.000657	CcSEcCtD
Risedronate—FDPS—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	0.000115	0.00364	CbGpPWpGaD
Risedronate—Infection—Epirubicin—urinary bladder cancer	0.000115	0.000655	CcSEcCtD
Risedronate—Cough—Doxorubicin—urinary bladder cancer	0.000114	0.000652	CcSEcCtD
Risedronate—PTGS2—Aryl Hydrocarbon Receptor—TNF—urinary bladder cancer	0.000114	0.00361	CbGpPWpGaD
Risedronate—Shock—Epirubicin—urinary bladder cancer	0.000113	0.000648	CcSEcCtD
Risedronate—Nervous system disorder—Epirubicin—urinary bladder cancer	0.000113	0.000646	CcSEcCtD
Risedronate—Hypertension—Doxorubicin—urinary bladder cancer	0.000113	0.000645	CcSEcCtD
Risedronate—PTGS2—Aryl Hydrocarbon Receptor—KRAS—urinary bladder cancer	0.000113	0.00358	CbGpPWpGaD
Risedronate—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	0.000112	0.000641	CcSEcCtD
Risedronate—Skin disorder—Epirubicin—urinary bladder cancer	0.000112	0.00064	CcSEcCtD
Risedronate—Insomnia—Methotrexate—urinary bladder cancer	0.000111	0.000637	CcSEcCtD
Risedronate—PTGS2—C-MYB transcription factor network—CDKN2A—urinary bladder cancer	0.000111	0.00353	CbGpPWpGaD
Risedronate—Arthralgia—Doxorubicin—urinary bladder cancer	0.000111	0.000636	CcSEcCtD
Risedronate—Chest pain—Doxorubicin—urinary bladder cancer	0.000111	0.000636	CcSEcCtD
Risedronate—Myalgia—Doxorubicin—urinary bladder cancer	0.000111	0.000636	CcSEcCtD
Risedronate—PTGS2—Spinal Cord Injury—CDK4—urinary bladder cancer	0.000111	0.00352	CbGpPWpGaD
Risedronate—Anxiety—Doxorubicin—urinary bladder cancer	0.000111	0.000634	CcSEcCtD
Risedronate—Paraesthesia—Methotrexate—urinary bladder cancer	0.000111	0.000632	CcSEcCtD
Risedronate—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	0.000111	0.000632	CcSEcCtD
Risedronate—Dyspnoea—Methotrexate—urinary bladder cancer	0.00011	0.000628	CcSEcCtD
Risedronate—Dry mouth—Doxorubicin—urinary bladder cancer	0.000109	0.000622	CcSEcCtD
Risedronate—Dyspepsia—Methotrexate—urinary bladder cancer	0.000108	0.00062	CcSEcCtD
Risedronate—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—urinary bladder cancer	0.000106	0.00337	CbGpPWpGaD
Risedronate—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.000106	0.000608	CcSEcCtD
Risedronate—Fatigue—Methotrexate—urinary bladder cancer	0.000106	0.000607	CcSEcCtD
Risedronate—Infection—Doxorubicin—urinary bladder cancer	0.000106	0.000606	CcSEcCtD
Risedronate—Pain—Methotrexate—urinary bladder cancer	0.000105	0.000602	CcSEcCtD
Risedronate—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	0.000105	0.0006	CcSEcCtD
Risedronate—Shock—Doxorubicin—urinary bladder cancer	0.000105	0.0006	CcSEcCtD
Risedronate—Nervous system disorder—Doxorubicin—urinary bladder cancer	0.000105	0.000598	CcSEcCtD
Risedronate—Insomnia—Epirubicin—urinary bladder cancer	0.000104	0.000596	CcSEcCtD
Risedronate—Skin disorder—Doxorubicin—urinary bladder cancer	0.000104	0.000592	CcSEcCtD
Risedronate—Paraesthesia—Epirubicin—urinary bladder cancer	0.000104	0.000592	CcSEcCtD
Risedronate—Dyspnoea—Epirubicin—urinary bladder cancer	0.000103	0.000587	CcSEcCtD
Risedronate—Dyspepsia—Epirubicin—urinary bladder cancer	0.000101	0.00058	CcSEcCtD
Risedronate—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.000101	0.000576	CcSEcCtD
Risedronate—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	9.95e-05	0.000569	CcSEcCtD
Risedronate—Fatigue—Epirubicin—urinary bladder cancer	9.94e-05	0.000568	CcSEcCtD
Risedronate—Constipation—Epirubicin—urinary bladder cancer	9.86e-05	0.000563	CcSEcCtD
Risedronate—Pain—Epirubicin—urinary bladder cancer	9.86e-05	0.000563	CcSEcCtD
Risedronate—PTGS2—Integrated Pancreatic Cancer Pathway—CCNE1—urinary bladder cancer	9.86e-05	0.00312	CbGpPWpGaD
Risedronate—Urticaria—Methotrexate—urinary bladder cancer	9.79e-05	0.000559	CcSEcCtD
Risedronate—Abdominal pain—Methotrexate—urinary bladder cancer	9.74e-05	0.000557	CcSEcCtD
Risedronate—Body temperature increased—Methotrexate—urinary bladder cancer	9.74e-05	0.000557	CcSEcCtD
Risedronate—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	9.72e-05	0.000555	CcSEcCtD
Risedronate—FDPS—Metabolism—NQO1—urinary bladder cancer	9.69e-05	0.00307	CbGpPWpGaD
Risedronate—PTGS2—Integrated Pancreatic Cancer Pathway—TYMS—urinary bladder cancer	9.68e-05	0.00307	CbGpPWpGaD
Risedronate—Insomnia—Doxorubicin—urinary bladder cancer	9.65e-05	0.000551	CcSEcCtD
Risedronate—PTGS2—Spinal Cord Injury—RB1—urinary bladder cancer	9.65e-05	0.00306	CbGpPWpGaD
Risedronate—PTGS2—Aryl Hydrocarbon Receptor—HRAS—urinary bladder cancer	9.59e-05	0.00304	CbGpPWpGaD
Risedronate—Paraesthesia—Doxorubicin—urinary bladder cancer	9.58e-05	0.000547	CcSEcCtD
Risedronate—Dyspnoea—Doxorubicin—urinary bladder cancer	9.51e-05	0.000544	CcSEcCtD
Risedronate—Gastrointestinal pain—Epirubicin—urinary bladder cancer	9.43e-05	0.000539	CcSEcCtD
Risedronate—FDPS—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	9.41e-05	0.00298	CbGpPWpGaD
Risedronate—PTGS2—C-MYB transcription factor network—CCND1—urinary bladder cancer	9.4e-05	0.00298	CbGpPWpGaD
Risedronate—Dyspepsia—Doxorubicin—urinary bladder cancer	9.39e-05	0.000537	CcSEcCtD
Risedronate—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	9.21e-05	0.000526	CcSEcCtD
Risedronate—Fatigue—Doxorubicin—urinary bladder cancer	9.2e-05	0.000526	CcSEcCtD
Risedronate—Urticaria—Epirubicin—urinary bladder cancer	9.16e-05	0.000523	CcSEcCtD
Risedronate—Pain—Doxorubicin—urinary bladder cancer	9.12e-05	0.000521	CcSEcCtD
Risedronate—Constipation—Doxorubicin—urinary bladder cancer	9.12e-05	0.000521	CcSEcCtD
Risedronate—Abdominal pain—Epirubicin—urinary bladder cancer	9.12e-05	0.000521	CcSEcCtD
Risedronate—Body temperature increased—Epirubicin—urinary bladder cancer	9.12e-05	0.000521	CcSEcCtD
Risedronate—PTGS2—C-MYB transcription factor network—CDKN1A—urinary bladder cancer	9.1e-05	0.00288	CbGpPWpGaD
Risedronate—Hypersensitivity—Methotrexate—urinary bladder cancer	9.08e-05	0.000519	CcSEcCtD
Risedronate—Asthenia—Methotrexate—urinary bladder cancer	8.84e-05	0.000505	CcSEcCtD
Risedronate—PTGS2—Spinal Cord Injury—RHOA—urinary bladder cancer	8.76e-05	0.00278	CbGpPWpGaD
Risedronate—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	8.72e-05	0.000499	CcSEcCtD
Risedronate—Pruritus—Methotrexate—urinary bladder cancer	8.72e-05	0.000498	CcSEcCtD
Risedronate—PTGS2—C-MYB transcription factor network—EP300—urinary bladder cancer	8.66e-05	0.00274	CbGpPWpGaD
Risedronate—PTGS2—Integrated Pancreatic Cancer Pathway—FAS—urinary bladder cancer	8.58e-05	0.00272	CbGpPWpGaD
Risedronate—Hypersensitivity—Epirubicin—urinary bladder cancer	8.5e-05	0.000485	CcSEcCtD
Risedronate—Urticaria—Doxorubicin—urinary bladder cancer	8.48e-05	0.000484	CcSEcCtD
Risedronate—Abdominal pain—Doxorubicin—urinary bladder cancer	8.43e-05	0.000482	CcSEcCtD
Risedronate—Body temperature increased—Doxorubicin—urinary bladder cancer	8.43e-05	0.000482	CcSEcCtD
Risedronate—Diarrhoea—Methotrexate—urinary bladder cancer	8.43e-05	0.000482	CcSEcCtD
Risedronate—Asthenia—Epirubicin—urinary bladder cancer	8.27e-05	0.000473	CcSEcCtD
Risedronate—FDPS—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	8.2e-05	0.0026	CbGpPWpGaD
Risedronate—Pruritus—Epirubicin—urinary bladder cancer	8.16e-05	0.000466	CcSEcCtD
Risedronate—Dizziness—Methotrexate—urinary bladder cancer	8.15e-05	0.000466	CcSEcCtD
Risedronate—FDPS—Metabolism—GSTP1—urinary bladder cancer	8.09e-05	0.00256	CbGpPWpGaD
Risedronate—Diarrhoea—Epirubicin—urinary bladder cancer	7.89e-05	0.000451	CcSEcCtD
Risedronate—Hypersensitivity—Doxorubicin—urinary bladder cancer	7.86e-05	0.000449	CcSEcCtD
Risedronate—PTGS2—Disease—GSTO2—urinary bladder cancer	7.85e-05	0.00249	CbGpPWpGaD
Risedronate—Vomiting—Methotrexate—urinary bladder cancer	7.83e-05	0.000448	CcSEcCtD
Risedronate—FDPS—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	7.82e-05	0.00248	CbGpPWpGaD
Risedronate—Rash—Methotrexate—urinary bladder cancer	7.77e-05	0.000444	CcSEcCtD
Risedronate—Dermatitis—Methotrexate—urinary bladder cancer	7.76e-05	0.000443	CcSEcCtD
Risedronate—Headache—Methotrexate—urinary bladder cancer	7.72e-05	0.000441	CcSEcCtD
Risedronate—PTGS2—Spinal Cord Injury—CXCL8—urinary bladder cancer	7.69e-05	0.00244	CbGpPWpGaD
Risedronate—Asthenia—Doxorubicin—urinary bladder cancer	7.65e-05	0.000437	CcSEcCtD
Risedronate—Dizziness—Epirubicin—urinary bladder cancer	7.62e-05	0.000436	CcSEcCtD
Risedronate—PTGS2—Integrated Pancreatic Cancer Pathway—ATM—urinary bladder cancer	7.58e-05	0.0024	CbGpPWpGaD
Risedronate—PTGS2—Integrated Pancreatic Cancer Pathway—CDK4—urinary bladder cancer	7.55e-05	0.00239	CbGpPWpGaD
Risedronate—Pruritus—Doxorubicin—urinary bladder cancer	7.55e-05	0.000431	CcSEcCtD
Risedronate—PTGS2—C-MYB transcription factor network—MYC—urinary bladder cancer	7.54e-05	0.00239	CbGpPWpGaD
Risedronate—PTGS2—Integrated Pancreatic Cancer Pathway—ESR1—urinary bladder cancer	7.52e-05	0.00238	CbGpPWpGaD
Risedronate—FDPS—Metabolism—TYMS—urinary bladder cancer	7.52e-05	0.00238	CbGpPWpGaD
Risedronate—FDPS—Metabolism—GSTM1—urinary bladder cancer	7.43e-05	0.00236	CbGpPWpGaD
Risedronate—FDPS—Metabolism—NCOR1—urinary bladder cancer	7.43e-05	0.00236	CbGpPWpGaD
Risedronate—PTGS2—Spinal Cord Injury—IL2—urinary bladder cancer	7.35e-05	0.00233	CbGpPWpGaD
Risedronate—Vomiting—Epirubicin—urinary bladder cancer	7.33e-05	0.000419	CcSEcCtD
Risedronate—Nausea—Methotrexate—urinary bladder cancer	7.32e-05	0.000418	CcSEcCtD
Risedronate—Diarrhoea—Doxorubicin—urinary bladder cancer	7.3e-05	0.000417	CcSEcCtD
Risedronate—Rash—Epirubicin—urinary bladder cancer	7.27e-05	0.000415	CcSEcCtD
Risedronate—Dermatitis—Epirubicin—urinary bladder cancer	7.26e-05	0.000415	CcSEcCtD
Risedronate—Headache—Epirubicin—urinary bladder cancer	7.22e-05	0.000413	CcSEcCtD
Risedronate—PTGS2—Spinal Cord Injury—CCND1—urinary bladder cancer	7.17e-05	0.00227	CbGpPWpGaD
Risedronate—FDPS—Metabolism—GPX1—urinary bladder cancer	7.12e-05	0.00226	CbGpPWpGaD
Risedronate—Dizziness—Doxorubicin—urinary bladder cancer	7.06e-05	0.000403	CcSEcCtD
Risedronate—FDPS—Metabolism—ERCC2—urinary bladder cancer	6.99e-05	0.00221	CbGpPWpGaD
Risedronate—PTGS2—C-MYB transcription factor network—KRAS—urinary bladder cancer	6.97e-05	0.00221	CbGpPWpGaD
Risedronate—PTGS2—Spinal Cord Injury—MMP9—urinary bladder cancer	6.96e-05	0.00221	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—GSTZ1—urinary bladder cancer	6.94e-05	0.0022	CbGpPWpGaD
Risedronate—Nausea—Epirubicin—urinary bladder cancer	6.85e-05	0.000391	CcSEcCtD
Risedronate—Vomiting—Doxorubicin—urinary bladder cancer	6.78e-05	0.000388	CcSEcCtD
Risedronate—PTGS2—Selenium Micronutrient Network—TNF—urinary bladder cancer	6.77e-05	0.00215	CbGpPWpGaD
Risedronate—Rash—Doxorubicin—urinary bladder cancer	6.73e-05	0.000384	CcSEcCtD
Risedronate—Dermatitis—Doxorubicin—urinary bladder cancer	6.72e-05	0.000384	CcSEcCtD
Risedronate—Headache—Doxorubicin—urinary bladder cancer	6.68e-05	0.000382	CcSEcCtD
Risedronate—PTGS2—Integrated Pancreatic Cancer Pathway—CREBBP—urinary bladder cancer	6.59e-05	0.00209	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—GSTO2—urinary bladder cancer	6.58e-05	0.00208	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—NAT1—urinary bladder cancer	6.58e-05	0.00208	CbGpPWpGaD
Risedronate—FDPS—Metabolism—MTHFR—urinary bladder cancer	6.57e-05	0.00208	CbGpPWpGaD
Risedronate—PTGS2—Integrated Pancreatic Cancer Pathway—IGF1—urinary bladder cancer	6.51e-05	0.00206	CbGpPWpGaD
Risedronate—PTGS2—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	6.47e-05	0.00205	CbGpPWpGaD
Risedronate—Nausea—Doxorubicin—urinary bladder cancer	6.34e-05	0.000362	CcSEcCtD
Risedronate—PTGS2—Disease—SLC19A1—urinary bladder cancer	6.11e-05	0.00194	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—UGT2B7—urinary bladder cancer	6.01e-05	0.00191	CbGpPWpGaD
Risedronate—PTGS2—Disease—PRSS3—urinary bladder cancer	5.95e-05	0.00189	CbGpPWpGaD
Risedronate—PTGS2—C-MYB transcription factor network—HRAS—urinary bladder cancer	5.92e-05	0.00188	CbGpPWpGaD
Risedronate—PTGS2—Spinal Cord Injury—MYC—urinary bladder cancer	5.75e-05	0.00182	CbGpPWpGaD
Risedronate—PTGS2—Disease—HDAC4—urinary bladder cancer	5.68e-05	0.0018	CbGpPWpGaD
Risedronate—PTGS2—Spinal Cord Injury—EGFR—urinary bladder cancer	5.62e-05	0.00178	CbGpPWpGaD
Risedronate—PTGS2—Integrated Pancreatic Cancer Pathway—ERBB2—urinary bladder cancer	5.52e-05	0.00175	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—CYP4B1—urinary bladder cancer	5.42e-05	0.00172	CbGpPWpGaD
Risedronate—PTGS2—Spinal Cord Injury—TNF—urinary bladder cancer	5.35e-05	0.0017	CbGpPWpGaD
Risedronate—FDPS—Metabolism—PPARG—urinary bladder cancer	5.32e-05	0.00169	CbGpPWpGaD
Risedronate—FDPS—Metabolism—CREBBP—urinary bladder cancer	5.12e-05	0.00162	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—SLC19A1—urinary bladder cancer	5.11e-05	0.00162	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—PRSS3—urinary bladder cancer	4.98e-05	0.00158	CbGpPWpGaD
Risedronate—PTGS2—Integrated Pancreatic Cancer Pathway—CCND1—urinary bladder cancer	4.87e-05	0.00155	CbGpPWpGaD
Risedronate—PTGS2—Spinal Cord Injury—TP53—urinary bladder cancer	4.72e-05	0.0015	CbGpPWpGaD
Risedronate—PTGS2—Integrated Pancreatic Cancer Pathway—CDKN1A—urinary bladder cancer	4.72e-05	0.00149	CbGpPWpGaD
Risedronate—PTGS2—Integrated Pancreatic Cancer Pathway—PTEN—urinary bladder cancer	4.7e-05	0.00149	CbGpPWpGaD
Risedronate—PTGS2—Disease—LIG1—urinary bladder cancer	4.51e-05	0.00143	CbGpPWpGaD
Risedronate—PTGS2—Integrated Pancreatic Cancer Pathway—EP300—urinary bladder cancer	4.49e-05	0.00142	CbGpPWpGaD
Risedronate—PTGS2—Integrated Pancreatic Cancer Pathway—SRC—urinary bladder cancer	4.36e-05	0.00138	CbGpPWpGaD
Risedronate—FDPS—Metabolism—PTGS2—urinary bladder cancer	4.19e-05	0.00133	CbGpPWpGaD
Risedronate—PTGS2—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	4e-05	0.00127	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—TYMP—urinary bladder cancer	3.98e-05	0.00126	CbGpPWpGaD
Risedronate—PTGS2—Integrated Pancreatic Cancer Pathway—MYC—urinary bladder cancer	3.91e-05	0.00124	CbGpPWpGaD
Risedronate—PTGS2—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	3.83e-05	0.00121	CbGpPWpGaD
Risedronate—PTGS2—Integrated Pancreatic Cancer Pathway—EGFR—urinary bladder cancer	3.82e-05	0.00121	CbGpPWpGaD
Risedronate—FDPS—Metabolism—PTEN—urinary bladder cancer	3.65e-05	0.00116	CbGpPWpGaD
Risedronate—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—urinary bladder cancer	3.64e-05	0.00115	CbGpPWpGaD
Risedronate—PTGS2—Integrated Pancreatic Cancer Pathway—KRAS—urinary bladder cancer	3.61e-05	0.00115	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—NAT2—urinary bladder cancer	3.6e-05	0.00114	CbGpPWpGaD
Risedronate—FDPS—Metabolism—EP300—urinary bladder cancer	3.48e-05	0.0011	CbGpPWpGaD
Risedronate—PTGS2—Disease—ENO2—urinary bladder cancer	3.44e-05	0.00109	CbGpPWpGaD
Risedronate—PTGS2—Disease—RBX1—urinary bladder cancer	3.26e-05	0.00103	CbGpPWpGaD
Risedronate—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	3.21e-05	0.00102	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—RRM2—urinary bladder cancer	3.11e-05	0.000986	CbGpPWpGaD
Risedronate—PTGS2—Disease—JAG1—urinary bladder cancer	2.92e-05	0.000925	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—ENO2—urinary bladder cancer	2.88e-05	0.000913	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—HPGDS—urinary bladder cancer	2.88e-05	0.000913	CbGpPWpGaD
Risedronate—PTGS2—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	2.86e-05	0.000908	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—GSTT1—urinary bladder cancer	2.79e-05	0.000886	CbGpPWpGaD
Risedronate—PTGS2—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	2.75e-05	0.000872	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—NQO1—urinary bladder cancer	2.32e-05	0.000736	CbGpPWpGaD
Risedronate—PTGS2—Disease—NCOR1—urinary bladder cancer	2.12e-05	0.000674	CbGpPWpGaD
Risedronate—PTGS2—Disease—ERCC2—urinary bladder cancer	2e-05	0.000633	CbGpPWpGaD
Risedronate—PTGS2—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.96e-05	0.000623	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—GSTP1—urinary bladder cancer	1.94e-05	0.000614	CbGpPWpGaD
Risedronate—PTGS2—Disease—MTHFR—urinary bladder cancer	1.88e-05	0.000595	CbGpPWpGaD
Risedronate—PTGS2—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.87e-05	0.000594	CbGpPWpGaD
Risedronate—PTGS2—Disease—TERT—urinary bladder cancer	1.87e-05	0.000594	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—TYMS—urinary bladder cancer	1.8e-05	0.000571	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—GSTM1—urinary bladder cancer	1.78e-05	0.000564	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—NCOR1—urinary bladder cancer	1.78e-05	0.000564	CbGpPWpGaD
Risedronate—PTGS2—Disease—FGFR3—urinary bladder cancer	1.72e-05	0.000545	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—GPX1—urinary bladder cancer	1.7e-05	0.00054	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—ERCC2—urinary bladder cancer	1.67e-05	0.00053	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—MTHFR—urinary bladder cancer	1.57e-05	0.000499	CbGpPWpGaD
Risedronate—PTGS2—Disease—CREBBP—urinary bladder cancer	1.46e-05	0.000464	CbGpPWpGaD
Risedronate—PTGS2—Disease—RHOA—urinary bladder cancer	1.32e-05	0.00042	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—PPARG—urinary bladder cancer	1.28e-05	0.000404	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—CREBBP—urinary bladder cancer	1.23e-05	0.000388	CbGpPWpGaD
Risedronate—PTGS2—Disease—ERBB2—urinary bladder cancer	1.23e-05	0.000388	CbGpPWpGaD
Risedronate—PTGS2—Disease—CDKN1A—urinary bladder cancer	1.05e-05	0.000332	CbGpPWpGaD
Risedronate—PTGS2—Disease—PTEN—urinary bladder cancer	1.04e-05	0.000331	CbGpPWpGaD
Risedronate—PTGS2—Disease—EP300—urinary bladder cancer	9.96e-06	0.000316	CbGpPWpGaD
Risedronate—PTGS2—Disease—SRC—urinary bladder cancer	9.69e-06	0.000307	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—PTEN—urinary bladder cancer	8.75e-06	0.000277	CbGpPWpGaD
Risedronate—PTGS2—Disease—MYC—urinary bladder cancer	8.68e-06	0.000275	CbGpPWpGaD
Risedronate—PTGS2—Disease—EGFR—urinary bladder cancer	8.49e-06	0.000269	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—EP300—urinary bladder cancer	8.34e-06	0.000265	CbGpPWpGaD
Risedronate—PTGS2—Disease—KRAS—urinary bladder cancer	8.02e-06	0.000254	CbGpPWpGaD
Risedronate—PTGS2—Disease—HRAS—urinary bladder cancer	6.82e-06	0.000216	CbGpPWpGaD
